In vivo modulation of N-myristoyltransferase activity by orthovanadate

  • Martin J. King
  • Subbiah Pugazhenthi
  • Ramji L. Khandelwal
  • Rajendra K. Sharma
Part of the Developments in Molecular and Cellular Biochemistry book series (DMCB, volume 16)


N-Myristoytransferase (NMT) catalyses the transfer of myristate from myristoyl-CoA to the NH2-terminal glycine residue of several proteins and are important in signal transduction. STZ-induced diabetes (an animal model for insulin-dependent diabetes mellitus, IDDM) resulted in a 2-fold increase in rat liver NMT activity as compared with control animals. In obese Zucker (fa/fa) rats (an animal model for non-insulin dependent diabetes mellitus, NIDDM) there was a ~4.7-fold lower liver particulate NMT activity as compared with the control lean rat livers. Administration of sodium orthovanadate to the diabetic rats normalised liver NMT activity. These results would indicate that the rat liver particulate N-myristoyltransferase activity appears to be inversely proportional to the level of plasma insulin, implicating insulin in the control of N-myristoylation.

Key words

sodium orthovanadate diabetes N-myristoyltransferase Liver membrane-associated vanadate obese Zucker rat 



N-myristoyl-CoA:protein N-myristoyltransferase


insulin-dependent diabetes mellitus


non-insulin-dependent diabetes mellitus


71 kDa N-myristoyltransferase inhibitor protein


45 kDa N-myristoyltransferase activating factor


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aitken A, Cohen P, Sandkarn S, Williams DH, Calder AG, Smith A, Klee CB: Identification of the NH2-terminal blocking group of calcineurin B as myristic acid. FEBS Lett 150: 314–318, 1982PubMedCrossRefGoogle Scholar
  2. 2.
    Buss JE, Kamps MP, Sefton BM: Myristic acid is attached to the transforming protein of Rous sarcoma virus during or immediately after synthesis and is present in both soluble and membrane-bound forms of the protein. Mol Cell Biol 4: 2697–2704, 1984PubMedGoogle Scholar
  3. 3.
    Carr SA, Biemann K, Shoji S, Parmellee DC, Titani K: n-Tetradecanoyl is the NH2-terminal blocking group of the catalytic subunit of cyclic AMP-dependent protein kinase from bovine cardiac muscle. Proc Natl Acad Sci USA 79: 6128–6131, 1982PubMedCrossRefGoogle Scholar
  4. 4.
    Duronio RJ, Towler DA, Heuckeroth RO, et al: Disruption of the yeast N-myristoyl transferase gene causes recessive lethality. Science 243: 796–800, 1989PubMedCrossRefGoogle Scholar
  5. 5.
    Kamps MP, Buss JE, Sefton BM: Mutation of NH2-terminal glycine of p60src prevents both myristoylation and morphological transformation. Proc Natl Acad Sci USA 82: 4625–4628, 1985PubMedCrossRefGoogle Scholar
  6. 6.
    Pugazhenthi S, Khandelwal RL, Angel JF: Insulin-like effect of vanadate on malic enzyme and glucose-6-phosphate dehydrogenase activities in streptozotocin-induced diabetic rat liver. Biochim Biophys Acta 1083: 310–312, 1991PubMedGoogle Scholar
  7. 7.
    Pugazhenthi S, Angel JF, Khandelwal RL: Long-term effects of vanadate treatment on glycogen metabolizing and lipogenic enzymes of liver in genetically diabetic (db/db) mice. Metabolism 40:941–946, 1991PubMedCrossRefGoogle Scholar
  8. 8.
    Khandelwal RL, Pugazhenthi S: In vivo effects of vanadate on hepatic glycogen metabolism and lipogenic enzymes in insulin-dependent and insulin-resistant diabetic animals. Mol Cell Biochem, this issue: 000–000, 1995Google Scholar
  9. 9.
    Hamel FG, Solomon SS, Stranik A, Blotcky A, Rack E, Duckworth WC: Alteration of tissue vanadium content in diabetes. Metabolism 42: 1503–1505, 1993PubMedCrossRefGoogle Scholar
  10. 10.
    Cros GH, Mongold JJ, Serrano JJ, McNeill JH: Enhanced in vivo sensitivity of vanadyl-treated diabetic rats to insulin. Can J Physiol Pharmacol 68: 486–491, 1990PubMedCrossRefGoogle Scholar
  11. 11.
    Duckworth WC, Solomon SS, Liepnieks J, Hamel FG, Hand S, Peavy DE: Insulin-like effects of vanadate in isolated rat adipocytes. Endocrinology 122: 2285–2289, 1988PubMedCrossRefGoogle Scholar
  12. 12.
    King MJ, Sale GJ: Insulin-receptor phosphotyrosyl-protein phosphatases. Biochem J 256: 893–902, 1988PubMedGoogle Scholar
  13. 13.
    King MJ, Sale GJ: Assay of phosphotyrosyl protein phosphatase using synthetic peptide 1142–1153 of the insulin receptor. FEBS Lett 237: 137–140, 1988PubMedCrossRefGoogle Scholar
  14. 14.
    Degani H, Gochin M, Karlish SDJ, ShechterY: Electron paramagnetic resonance studies and insulin-like effects of vanadium in rat adipocytes. Biochemistry 20: 5795–5799, 1981PubMedCrossRefGoogle Scholar
  15. 15.
    Smith DM, Sale G J: Evidence that a novel serine kinase catalyses phosphorylation of the insulin receptor in an insulin-dependent and tyrosine kinase-dependent manner. Biochem J 256: 903–909, 1988PubMedGoogle Scholar
  16. 16.
    Sale GJ: Recent progress in our understanding of the mechanism of action of insulin. Int J Biochem 20: 897–908, 1988PubMedCrossRefGoogle Scholar
  17. 17.
    Ramanadham SA, Mongold JJ, Brownsey RW, Cros GH, McNeill JH: Oral vanadyl sulphate in treatment of diabetes mellitus in rats. Am J Physiol 257: H904–H911, 1989PubMedGoogle Scholar
  18. 18.
    Pugazhenthi S, Khandelwal RL: Insulinlike effects of vanadate on hepatic glycogen metabolism in nondiabetic and streptozotocin-induced diabetic rats. Diabetes 39: 821–827, 1990PubMedCrossRefGoogle Scholar
  19. 19.
    Macara IG, Kustin K, Cantley LC: Glutathione reduces cytoplasmic vanadate mechanism and physiological implications. Biochim Biophys Acta 629: 95–106, 1980PubMedGoogle Scholar
  20. 20.
    King MJ, Sharma RK: N-myristoyl transferase assay using phosphocellulose paper binding. Anal Biochem 199: 149–153, 1991PubMedCrossRefGoogle Scholar
  21. 21.
    King MJ, Pugazhenthi S, Khandelwal RL, Sharma RK: Elevated N-myristoyl transferase activity is reversed by sodium orthovanadate in streptozotocin-induced diabetic rat. Bioch Biophys Acta 1165: 259–262, 1993Google Scholar
  22. 22.
    King MJ, Pugazhenthi S, Khandelwal RL, Sharma RK: Membrane-associated N-myristoyltransferase activity is reduced in obese (fa/fa) Zuckerrat liver. Biochem Biophys Res Commun 196: 665–670, 1993PubMedCrossRefGoogle Scholar
  23. 23.
    King MJ, Sharma RK: Identification, purification and characteriztion of a membrane-associated N-myristoyltransferase inhibitor protein from bovine brain. Biochem J 291: 635–639, 1993PubMedGoogle Scholar
  24. 24.
    King MJ, Sharma RK: Differential activation of bovine brain N-myristoyltransferase(s) by a cytosolic activator. Biochem Biophys Res Commun 212: 580–588, 1995PubMedCrossRefGoogle Scholar
  25. 25.
    Mcllhinney RAJ, McGlone K: Characterisation of a myristoyl CoA:glycylpeptide N-myristoyl transferase activity in rat brain: Subcellular and regional distribution. J Neurochem 54:110–117,1990CrossRefGoogle Scholar
  26. 26.
    King MJ, Sharma RK: Demonstration of multiple forms of bovine brain myristoyl CoA:protein N-myristoyl transferase. Mol Cell Biochem 113: 77–81, 1992PubMedCrossRefGoogle Scholar
  27. 27.
    Boutin JA, Ferry G, Ernould A-P, Maes P, Remond G, Vincent M: Myristoyl-CoA:protein N-myristoyltransferase activity in cancer cells. Purification and characterisation of a cytosolic isoform from the murine leukemia cell line L1210. Eur J Biochem 214: 853–867, 1993PubMedCrossRefGoogle Scholar
  28. 28.
    Klarland JK: Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins. Cell 41: 707–717, 1985CrossRefGoogle Scholar
  29. 29.
    King MY, Sale GJ: Dephosphorylation of insulin-receptor autophosphorylation sites by particulate and soluble phosphotyrosyl-protein phosphatases. Biochem J 266:251–259, 1990PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Martin J. King
    • 1
  • Subbiah Pugazhenthi
    • 2
  • Ramji L. Khandelwal
    • 2
  • Rajendra K. Sharma
    • 3
  1. 1.Saskatoon Cancer CentreSaskatoonCanada
  2. 2.Department of BiochemistryUniversity of SaskatchewanSaskatoonCanada
  3. 3.Department of Pathology and Saskatoon Cancer Centre, Royal University HospitalUniversity of SaskatchewanSaskatoonCanada

Personalised recommendations